These findings challenge previous assumptions about the homodimerization status of PTH1R and highlight how ligand dimerization, rather than receptor dimerization, governs PTH1R activation dynamics and location-biased cAMP signaling, offering mechanistic insights relevant to therapeutic strategies against hypoparathyroidism. This evidence concerns the gene PTH1R and hypoparathyroidism.